Big Pharma Delays Release of Generic Drugs
Congress should use health reform to ban “pay-for-delay” deals
Lawmakers should include a provision in the health reform bill that would prevent brand-name drugmakers from entering into “pay-for-delay” deals with generic drug firms as a way to maintain the market exclusivity of their products, according to this Washington Post editorial. The practice forces government health insurance programs to pay billions of dollars for expensive treatments and consumers to lose an average of $3.5 billion annually in possible savings, the editorial adds. The Washington Post
No comments yet.